FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to nasally-administered anti-influenza virus vaccine compositions effective in non-immunised subjects such as children. To this end, a composition comprising one or more non-living antigens selected from the group consisting of a whole inactivated virus, a split virus, subunit antigen of influenza and recombinant antigens, and an adjuvant containing one or more carboxylic acids, an aqueous medium and one or more monoglycerides are administered intranasally to subjects of infant age ranging from a newborn to 18 years of age.
EFFECT: invention reduces the release of the virus into the environment.
17 cl, 6 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION FOR USE IN IMMUNO-COMPROMISED POPULATIONS | 2013 |
|
RU2661408C2 |
| MUCOSAL INFLUENZA VIRUS VACCINE AND METHOD FOR INFLUENZA PREVENTION | 2004 |
|
RU2390351C2 |
| INFLUENZA VACCINE | 2014 |
|
RU2546861C1 |
| FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPs) | 2006 |
|
RU2483751C2 |
| COMPUTER-OPTIMIZED ANTIGENS WITH WIDE REACTIVITY SPECTRUM FOR INFLUENZA VIRUSES OF H5N1 AND H1N1 | 2013 |
|
RU2639551C2 |
| VACCINE COMPOSITION | 2013 |
|
RU2655627C2 |
| POLYVALENT VACCINE AGAINST INFLUENZA BASED ON NANOPARTICLES | 2019 |
|
RU2805552C2 |
| INFLUENZA VACCINE | 2011 |
|
RU2583297C2 |
| IMMUNOGENIC COMPOSITIONS AND METHODS | 2008 |
|
RU2468034C2 |
| RECOMBINANT TRIVALENT INFLUENZA VACCINE | 2012 |
|
RU2485973C1 |
